Extension CombiRx Data Show No Benefit of Combined MS DrugsExtension CombiRx Data Show No Benefit of Combined MS Drugs
Seven-year results of a large trial comparing a combination of interferon-beta1a and glatiramer acetate to monotherapy with either drug alone continue to show no additional benefit of the combination therapy. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 21, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Less frequent glatiramer acetate (Copaxone)
A study presented at AAN found that people taking a double dose of Copaxone three times a week showed a reduction in the relapse rate of about a third compared to placebo. Although not studied against the daily dose, the effects are similar. Results presented at the AAN (American Academy of Neurology) meeting.
Internal Medicine News
Glatiramer acetate (Copaxone) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - March 20, 2013 Category: Neurology Source Type: news
Common MS Drugs Taken Together Do Not Reduce Relapse Risk
A recent clinical trial found that interferonβ-1a (INF) and glatiramer acetate (GA), two of the most commonly prescribed drugs for multiple sclerosis (MS), provide no additional clinical benefit when taken together. While findings published today in Annals of Neurology, a journal of the American Neurological Association and Child Neurology Society, suggest that taking both INF and GA together was not superior to GA monotherapy in reducing relapse risk; the combination therapy does appear to reduce new lesion activity and total lesion volume... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 13, 2013 Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news
Common MS drugs taken together do not reduce relapse risk
(Wiley) A recent clinical trial found that interferonβ-1a and glatiramer acetate, two of the most commonly prescribed drugs for multiple sclerosis (MS), provide no additional clinical benefit when taken together. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 11, 2013 Category: Global & Universal Source Type: news
Beta interferon / Copaxone combination
A study compared people taking both beta interferon (Avonex) and glatiramer acetate (Copaxone) with people taking either of the drugs on its own. The results showed no difference in effect on progression or improvement in, but the combination and Copaxone alone were both better at reducing the relapse rate and the combination reduced the number of new lesions.
Science Daily
Disease modifying drugs - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - March 11, 2013 Category: Neurology Source Type: news
Glatiramer Acetate Exposure in Pregnant Patients With MSGlatiramer Acetate Exposure in Pregnant Patients With MS
Is the immunomodulator glatiramer acetate safe to continue in MS patients contemplating pregnancy? BMC Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Teva Files for Copaxone-Laquinimod Patent
BRIEF: Teva Files for Copaxone-Laquinimod Patent [Globes, Tel
Aviv, Israel]
From Globes (Tel Aviv) (February 13, 2013)
Feb. 13--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE:
TEVA) has filed for a US patent for a Copaxone-Laquinimod... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 14, 2013 Category: Pharmaceuticals Source Type: news
Teva questions safety of rival MS drug BG-12
Source: Reuters
Area: News
Teva Pharmaceutical Industries Ltd, which markets glatiramer (Copaxone) has filed a petition with the FDA that could, if granted, delay entry to the market of a rival drug (dimethyl fumarate/ BG-12) developed by Biogen Idec Inc.
Teva's petition asks the FDA not to approve any new multiple sclerosis drug until its safety has been evaluated by a panel of outside advisors, and said it had uncovered information on a publicly accessible website about the safety of Biogen's drug; namely that kidney changes were observed after repeated administration of BG-12 in mice, rats, dogs and monkeys...
Source: NeLM - News - January 11, 2013 Category: Drugs & Pharmacology Source Type: news
Teva Raises Copaxone Price Another 10 Percent
[Globes, Tel Aviv,
Israel]
From Globes (Tel Aviv) (January 9, 2013)
Jan. 09--As in previous years, Teva Pharmaceutical Industries
Ltd. (NYSE: TEVA; TASE: TEVA) raised the price of Copaxone, its
brand... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 10, 2013 Category: Pharmaceuticals Source Type: news
Teva questions safety of MS drug from rival Biogen
(Reuters) - Teva Pharmaceutical Industries Ltd, which makes the market-leading multiple sclerosis drug Copaxone, has filed a petition with the U.S. Food and Drug Administration that could, if granted, delay entry to the market of a rival drug developed by Biogen Idec Inc. (Source: Reuters: Health)
Source: Reuters: Health - January 9, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
